NCT04391179

Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: University of Michigan · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The most severe manifestations of COVID-19 include respiratory failure, coagulation problems, and death. Inflammation and blood clotting are believed to play an important role in these manifestations. Research in humans has shown that dipyridamole can reduce blood clotting. This research study is being conducted to learn whether 14 days of treatment with dipyridamole will reduce excessive blood clotting in COVID-19. This study will enroll participants with confirmed coronavirus (SARS-CoV)-2 infection that are admitted. Eligible participants will be randomized to receive dipyridamole or placebo for 14 days in the hospital. In addition, data will be collected from the medical record, and there will also be blood draws during the hospitalization.

Conditions

• COVID
• Corona Virus Infection
• Covid-19
• SARS-CoV-2 Infection

Interventions

Type	Name	Description
DRUG	Dipyridamole 100 Milligram(mg)	Drug will be given for 14 days while in the hospital.
DRUG	Placebo oral tablet	Placebo will be given for 14 days while in the hospital.

Timeline

• Start date: 2020-05-31
• Primary completion: 2021-02-22
• Completion: 2021-02-22
• First posted: 2020-05-18
• Last updated: 2022-03-24
• Results posted: 2022-03-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study